Premium
Angiocentric glioma: elevated proliferation rate at clinical presentation does not preclude extended recurrence‐free survival
Author(s) -
Li Jianyi,
Langford Lauren A,
Adesina Adekunle,
Bodhireddy Surender R,
Wang Min,
Fuller Gregory N
Publication year - 2008
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.22.1_supplement.706.6
Subject(s) - immunostaining , medicine , ki 67 , presentation (obstetrics) , mitotic index , temporal lobe , pathology , frontal lobe , glioma , immunohistochemistry , radiology , mitosis , biology , epilepsy , cancer research , psychiatry , microbiology and biotechnology
Background: Angiocentric glioma (AG) is a recently described brain tumor with mixed features of ependymal and diffuse astrocytic differentiation that has been formally codified in 2007 WHO Classification of Tumours of the Central Nervous System. AGs characteristically exhibit low proliferation rates, with Ki‐67 labeling indices ranging from less than 1% to 5%. A single case with anaplastic recurrence and a labeling index of 10% has been reported. In the present study, we report a series of AGs that includes one case with an elevated proliferation rate at presentation that nonetheless has shown protracted recurrence‐free survival. Case reports: Case1, 4‐yo with a history of seizures and a frontal lobe mass. Case 2, 9‐yo with recent onset partial complex seizures and a temporal lobe mass. Case 3, 4‐yo with pervasive developmental delay, seizure disorder, and a frontal lobe mass. All three tumors showed classic histopathologic and immunophenotypic features of AG. The tumor from case 1 had 6 mitoses per 10 HPF, which were quickly and reliably quantitated using an anti‐phosphohistone H3 immunostain. Anti‐pHH3 immunostaining showed rare mitoses in cases 2 and 3. Postoperative recurrence‐free survivals for the three patients were 6 years, 9 years, and 5 months, respectively. Conclusion: Although anaplastic progression of AG has been reported, the presence of brisk mitotic activity at clinical presentation does not, per se, preclude extended recurrence‐free survival.